2016 American Transplant Congress
Monitoring of De Novo DSA Post Alemtuzumab Induction in Renal Transplant Recipients: One Year Follow Up.
Nephrology & Hypertension, Stony Brook Medicine, Stony Brook, NY.
IntroductionThe presence of de novo DSA (dnDSA) is associated with antibody mediated rejection and less optimal graft outcomes. The overall incidence of dnDSA post renal…2016 American Transplant Congress
Mycophenolic Acid Product Discontinuation Prior to Conception: Analysis of Pregnancies in Kidney Transplant Recipients.
Mycophenolic acid (MPA) products are considered teratogenic and transplant centers report discontinuing MPA in female kidney recipients anticipating pregnancy. Data were collected by the National…2016 American Transplant Congress
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study.
The NEVERWOUND study was designed to evaluate the impact of immediate vs. delayed introduction of everolimus (EVR) on wound healing complications (WHC) and delayed graft…2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…2016 American Transplant Congress
Mothers Are Often Sensitized and Sensitive: Antibody Mediated Rejection in Child to Mother Living Donor Liver Transplantation.
Background: Partial graft is especially more vulnerable to deleterious effects of donor specific HLA antibodies (DSA). Living liver donors and recipients are often family members.…2016 American Transplant Congress
Clinical Rejection-Risk Assessment with Allospecific CD154+T-Cytotoxic Memory Cells (CD154+TcM) After Pediatric Liver or Intestine Transplantation (LTx, ITx).
Surgery, Children's Hosp of Pgh of UPMC & Univ of Pittsburgh, Pittsburgh, PA.
Background: In preclinical evaluation, CD154+TcM predict acute cellular rejection after LTx or ITx with sensitivity/specificity of 80%. Purpose/Methods: To summarize test indications and performance during…2016 American Transplant Congress
Proteoforms: Novel Biomarkers for Acute Rejection in Liver Transplant Recipients.
1Northwestern, Chicago; 2UPMC, Pittsburgh.
Background: Biomarker profiles diagnostic of acute rejection (AR) in liver transplant (LT) recipients could enhance the diagnosis and management of recipients. Our aim was to…2016 American Transplant Congress
Profiling Immunologic Risk for Acute Rejection in Liver Transplantation: Recipient Age Is a Robust Risk Factor.
Profiling the immunologic risk for acute rejection in liver transplantation (OLT) may allow for selection immunosuppression (IS) target ranges appropriate to risk levels, all with…2016 American Transplant Congress
A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation.
Transplant Surgery, New York University Langone Medical Center, New York, NY.
Acute cellular rejection following liver transplantation has decreased in incidence with the use of potent immunosuppressive agents, affecting less than 25 percent of liver transplantation…2016 American Transplant Congress
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.
Background: The H2304 and PROTECT studies demonstrated reduced nephrotoxicity with everolimus (EVR)-based calcineurin inhibitor (CNI; cyclosporine: CsA, tacrolimus: TAC)-free regimens at Month (M) 12. Here,…
American Transplant Congress abstracts